{"entity":{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","aka":[],"tldr":"A phase 2 trial of IMC-001 in peripheral T-cell lymphomas, run by ImmuneOncia Therapeutics Inc., active and no longer recruiting.","summary":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type is a phase 2 interventional study registered as NCT04414163 by ImmuneOncia Therapeutics Inc., with 23 participants enrolled, started 2020-10-27 and due to reach its primary completion in 2024-07-23. Interventions recorded: IMC-001.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04414163","url":"https://clinicaltrials.gov/study/NCT04414163"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04414163","phase":"2","setting":"An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","sponsor":"ImmuneOncia Therapeutics Inc.","enrolled":23,"outcomes":[]},"route":"/trials/nct04414163/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}